A practical reference on GHRH receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-27 and is reviewed periodically as new material appears.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
== Z == Richard Zare (born 1939), American chemist, 2005 Wolf Prize in Chemistry Nikolay Zefirov (1935-2017), Russian and Soviet Organic and Medicinal Chemist Nikolay Zelinsky (1861–1953), Russian and Soviet Organic chemist, inventor of the first effective gas mask (1915) Ahmed H. Zewail (1946–2016), Egyptian chemist, 1999 Nobel Prize in Chemistry for his work on femtochemistry Karl Ziegler (1898–1973), German chemist, 1963 Nobel Prize in Chemistry Richard Adolf Zsigmondy (1865–1929), 1925 Nobel Prize in Chemistry
====== Naloxone distribution ====== Naloxone is a drug used to counter an overdose from the effect of opioids; for example, a heroin or morphine overdose. Naloxone displaces the opioid molecules from the brain's receptors and reverses the respiratory depression caused by an overdose within two to eight minutes. The World Health Organization (WHO) includes naloxone on their "List of Essential Medicines", and recommends its availability and utilization for the reversal of opioid overdoses. Formal programs in which the opioid inverse agonist drug naloxone is distributed have been trialled and implemented. Established programs distribute naloxone, as per WHO's minimum standards, to people who use substances and their peers, family members, police, prisons, and others. These treatment programs and harm reduction centres operate in Afghanistan, Australia, Canada, China, Germany, Georgia, Kazakhstan, Norway, Russia, Spain, Tajikistan, the United Kingdom (UK), the United States (US), Vietnam, India, Thailand, Kyrgyzstan, Denmark and Estonia. Many reviews of the literature support the effectiveness of naloxone based interventions in reducing overdose deaths where it is available at the time of the overdose event.
In March 2014, the IOC Disciplinary Commission decided that Bäckström would be awarded the silver medal. In January 2015 Bäckström, the IOC, WADA and the IIHF agreed to a settlement in which he accepted a reprimand but was cleared of attempting to enhance his performance.
The cause of the 2006 death of Alexander Litvinenko, a former Russian FSB agent who had defected to the United Kingdom in 2001, was identified to be poisoning with a lethal dose of 210Po; it was subsequently determined that the 210Po had probably been deliberately administered to him by two Russian ex-security agents, Andrey Lugovoy and Dmitry Kovtun. As such, Litvinenko's death was the first (and, to date, only) confirmed instance in which polonium's extreme toxicity has been used with malicious intent. In 2011, an allegation surfaced that the death of Palestinian leader Yasser Arafat, who died on 11 November 2004 of uncertain causes, also resulted from deliberate polonium poisoning, and in July 2012, concentrations of 210Po many times more than normal were detected in Arafat's clothes and personal belongings by the Institut de Radiophysique in Lausanne, Switzerland. Even though Arafat's symptoms were acute gastroenteritis with diarrhoea and vomiting, the institute's spokesman said that despite the tests the symptoms described in Arafat's medical reports were not consistent with 210Po poisoning, and conclusions could not be drawn. In 2013 the team found levels of polonium in Arafat's ribs and pelvis 18 to 36 times the average, even though by this point in time the amount had diminished by a factor of 2 million. Forensic scientist Dave Barclay stated, "In my opinion, it is absolutely certain that the cause of his illness was polonium poisoning. ...
Sources: en.wikipedia.org
== History == Dino Martin, Desi Arnaz Jr. and Billy Hinsche first met in grammar school. Due to the family connections of Dino and Desi, the band's first audition was for Frank Sinatra, who founded and still had an interest in Reprise Records, the recording label for Dean Martin. Though Arnaz, whose father was a famous drummer and who had learned to play drums from close family friend Richard Keith (who played Little Ricky on I Love Lucy) was a skilled drummer in his own right, the group did not play their own instruments on most of their records, instead using top session players, producers and songwriters. Producers included Lee Hazlewood, Billy Strange and Jimmy Bowen. Songwriters whose compositions were recorded by the group included Hazlewood, Red West, David Gates, Boyce and Hart, Clint Ballard Jr. and Bonner & Gordon. Dino, Desi & Billy's best known songs were "I'm a Fool" (1965; U.S. Billboard Hot 100 No. 17; later covered by Alvin and the Chipmunks for their 1965 album Chipmunks à Go-Go) and "Not the Lovin' Kind" (1965; U.S. No. 25). Both were hits for the group before any group member had reached the age of 15. Following this success, in 1965, they toured as an opening act for the Beach Boys. The group also opened for Paul Revere & the Raiders, Tommy Roe, Sam the Sham, the Lovin' Spoonful and the Mamas & the Papas. The band did not have a top 40 hit after 1965, despite releasing records for five years thereafter.
The Jackson Labs DO (Diversity Outbred) project is a mouse breeding program using multiple inbred founder strains to create a genetically diverse population of mice for use in scientific research. These mice are designed for fine genetic mapping, and capture a large portion of the genetic diversity of the mouse genome. This project has resulted in over 1,000 genetically diverse mice which have been used to identify genetic factors for diseases such as obesity, cancer, diabetes, and alcohol use disorder.
== Moscow rings == Moscow's road system is approximately centered around the Kremlin at the city's core. From there, roads generally radiate outward to intersect with a series of circular roads ("rings"):
The combination of aerobic activity and cryotherapy may be an innovative therapeutic strategy to improve the aerobic capacity in arthritis patients and consequently reduce their cardiovascular risk while minimizing pain and disease activity. Emerging rehabilitation strategies have also highlighted the benefits of low-intensity resistance training combined with blood flow restriction for individuals with rheumatoid arthritis. This rehabilitation approach allows patients to improve muscle strength, muscle hypertrophy, and functional performance while placing less mechanical stress on the affected joints, making it ideal for individuals experiencing pain, joint instability, or reduced tolerance to resistance exercise. Incorporating blood flow restriction training into physical therapy programs may be beneficial in supporting the maintenance of muscle function and independence in activities of daily living and is evidence based.
Astrophysicist Makoto Inoue and economist Hiromitsu Yokoo have explored the possibility that a Type III civilization could extract energy from a supermassive black hole (SMBH). The captured energy could meet the extraordinary needs of a civilization that requires about 4×1044 ergs/s. The energy would be captured in the form of radiation emitted by the matter rushing into the star, by means of collectors located within the accretion disk. These collectors are similar to Dyson spheres. The overflow, as well as the waste of the civilization, would be redirected towards the black hole. A fraction of this energy, directed as a high-powered beam, could be useful for space travel. A galactic club of civilizations could transmit the energy through networks within the galaxy. Within the various central power stations that make up the network, power transmission is periodically switched between transmitter and receiver, according to the galactic rotation. To be efficient, this network should be located at the center of the galaxy.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.